Filtered By:
Condition: Atrial Fibrillation
Procedure: Percutaneous Coronary Intervention

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 371 results found since Jan 2013.

Incidence, Trends, and Predictors of Ischemic Stroke 30 Days After an Acute Myocardial Infarction Clinical Sciences
Conclusions— The incidence of ischemic stroke within 30 days of an AMI has decreased during the period 1998 to 2008. This decrease is associated with increased use of acetylsalicylic acid, P2Y12 inhibitors, statins, and percutaneous coronary intervention.
Source: Stroke - April 28, 2014 Category: Neurology Authors: Kajermo, U., Ulvenstam, A., Modica, A., Jernberg, T., Mooe, T. Tags: Risk Factors, Acute myocardial infarction, Acute Cerebral Infarction, Epidemiology Clinical Sciences Source Type: research

Incidence, Trends, and Predictors of Ischemic Stroke 1 Year After an Acute Myocardial Infarction Clinical Sciences
Conclusions— The risk of ischemic stroke within a year after myocardial infarction is substantial but has clearly been reduced during the studied time period. The major predictive factors found to correlate well with previous investigations. Reperfusion treatment, thrombocyte aggregation inhibition, and lipid lowering are the main contributors to the observed risk reduction.
Source: Stroke - October 27, 2014 Category: Neurology Authors: Ulvenstam, A., Kajermo, U., Modica, A., Jernberg, T., Soderstrom, L., Mooe, T. Tags: Platelet function inhibitors, Acute myocardial infarction, Acute Cerebral Infarction, Platelets Clinical Sciences Source Type: research

Beyond Stroke Prevention in Atrial Fibrillation: Exploring Further Unmet Needs with Rivaroxaban.
This article provides an update on three randomized controlled trials of rivaroxaban, a direct, oral factor Xa inhibitor, that are complete or are ongoing, in these unmet areas of stroke prevention: oPen-label, randomized, controlled, multicentre study explorIng twO treatmeNt stratEgiEs of Rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in patients with Atrial Fibrillation who undergo Percutaneous Coronary Intervention (PIONEER AF-PCI) trial; the New Approach riVaroxaban Inhibition of factor Xa in a Global trial vs Aspirin to prevenT Embolism in Embolic Stroke of Undetermined Source (NAVIGATE E...
Source: Thrombosis and Haemostasis - March 22, 2018 Category: Hematology Authors: Gibson CM, Hankey GJ, Nafee T, Welsh RC Tags: Thromb Haemost Source Type: research

Cardioembolic Stroke - Postmyocardial Infarction Stroke
Ischemic stroke following acute myocardial infarction (AMI) is a rare but serious complication due to left ventricular thrombus formation and atrial fibrillation. Early revascularization of the culprit coronary lesion is essential. Treatment trends may affect the risk. Conversely, the greater use of antiplatelet agents to reduce the risk of ischemic stroke could increase the risk of hemorrhagic stroke. The risk of stroke after AMI has decreased significantly with more use of percutaneous coronary intervention and antithrombotic therapies in the acute setting, and statins, antihypertensive medications, and dual antiplatelet...
Source: Cardiology Clinics - March 12, 2016 Category: Cardiology Authors: Marius Hornung, Jennifer Franke, Sameer Gafoor, Horst Sievert Source Type: research

Cardioembolic Stroke and Postmyocardial Infarction Stroke
Ischemic stroke following acute myocardial infarction (AMI) is a rare but serious complication due to left ventricular thrombus formation and atrial fibrillation. Early revascularization of the culprit coronary lesion is essential. Treatment trends may affect the risk. Conversely, the greater use of antiplatelet agents to reduce the risk of ischemic stroke could increase the risk of hemorrhagic stroke. The risk of stroke after AMI has decreased significantly with more use of percutaneous coronary intervention and antithrombotic therapies in the acute setting, and statins, antihypertensive medications, and dual antiplatelet...
Source: Cardiology Clinics - March 11, 2016 Category: Cardiology Authors: Marius Hornung, Jennifer Franke, Sameer Gafoor, Horst Sievert Source Type: research

Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1
<span class="paragraphSection">Patients with atrial fibrillation (AF) have a high risk of stroke and mortality, which can be considerably reduced by oral anticoagulants (OAC). Recently, four non-vitamin-K oral anticoagulants (NOACs) were compared with warfarin in large randomized trials for the prevention of stroke and systemic embolism. Today's clinician is faced with the difficult task of selecting a suitable OAC for a patient with a particular clinical profile or a particular pattern of risk factors and concomitant diseases. We reviewed analyses of subgroups of patients from trials of vitamin K antagonists vs. NOA...
Source: European Heart Journal - February 4, 2016 Category: Cardiology Source Type: research

Left Atrial Size and Ischemic Events after Ischemic Stroke or Transient Ischemic Attack in Patients with Nonvalvular Atrial Fibrillation
Conclusion: Severe LAE was associated with increased risk of ischemic events after ischemic stroke or TIA in patients with NVAF.Cerebrovasc Dis
Source: Cerebrovascular Diseases - November 11, 2020 Category: Neurology Source Type: research

Simultaneous onset of myocardial infarction and ischemic stroke in a patient with atrial fibrillation: Multiple territory injury revealed on angiography and magnetic resonance
An 84-year-old man with a history of hypertension and paroxysmal atrial fibrillation (AF) who received no anticoagulant drugs experienced acute chest pain and transient loss of consciousness. He was transferred to our emergency room. His initial electrocardiogram showed sinus rhythm with ST-segment elevation in the I, aVL, and V1–V6 leads. His blood pressure was 158/92mmHg and his pulse was regular at 70beats per minute. A chest radiograph showed increased heart size and pulmonary vascular congestion. His troponin T level was elevated (more than 0.1ng/mL). He was diagnosed with ST-elevation myocardial infarction (MI) and...
Source: International Journal of Cardiology - February 4, 2014 Category: Cardiology Authors: Osamu Hashimoto, Kozo Sato, Yohei Numasawa, Joji Hosokawa, Masahiro Endo Tags: Online Letters to the Editor Source Type: research

Global longitudinal strain predicts incident atrial fibrillation and stroke occurrence after acute myocardial infarction
Abstract: Patients with acute myocardial infarction are at increased risk of developing atrial fibrillation. We aimed to evaluate whether speckle tracking echocardiography improves risk stratification for atrial fibrillation in these patients. The study comprised of 373 patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention. Patients had an echocardiogram performed at a median of 2 days after their STEMI. The echocardiograms consisted of conventional measurements and myocardial strain analysis by speckle tracking from 3 apical projections. The endpoint was ...
Source: Medicine - November 1, 2016 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research

Triggering of Stroke or Atrial Fibrillation by Percutaneous Coronary Intervention
I have read the article entitled “Percutaneous Coronary Intervention as a Trigger for Stroke” by Varmdal et al. 1 with great interest, recently published in journal. Their estimates indicated a substantially increased risk of ischemic stroke during the first 2 days after percutaneous coronary intervention (PCI). Relative risk t hen decreased gradually but stayed elevated for 8 weeks. Increased awareness of this vulnerable period after PCI in clinicians and patients could contribute to earlier detection and treatment for patients suffering a postprocedural stroke 1.
Source: The American Journal of Cardiology - January 2, 2017 Category: Cardiology Authors: Levent Cerit Source Type: research

Effects of Smoking on Ischemic Stroke, Intracranial Hemorrhage, and Coronary Artery Events in Japanese Patients With Non-Valvular Atrial Fibrillation.
Authors: Suzuki S, Otsuka T, Sagara K, Semba H, Kano H, Matsuno S, Takai H, Kato Y, Uejima T, Oikawa Y, Nagashima K, Kirigaya H, Yajima J, Kunihara T, Sawada H, Aizawa T, Yamashita T Abstract The effects of smoking on the prognosis of non-valvular atrial fibrillation (NVAF) patients are unclear.The Shinken Database 2004-11 (n = 17,517) includes all new patients visiting the Cardiovascular Institute between June 2004 and March 2012. Among these cases, 2,102 NVAF patients were identified. The effects of smoking on ischemic stroke (IS), intracranial hemorrhage (ICH), and coronary artery events including percutaneous c...
Source: International Heart Journal - July 15, 2017 Category: Cardiology Tags: Int Heart J Source Type: research

Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after PCI: An ancillary analysis from the RE-DUAL PCI trial
ConclusionDabigatran dual therapy reduced bleeding events irrespective of bleeding risk category and demonstrated similar efficacy regardless of stroke risk category when compared with warfarin triple therapy.
Source: American Heart Journal - March 4, 2019 Category: Cardiology Source Type: research

Prevalence and Determinants of Atrial Fibrillation-associated In-hospital Ischemic Stroke in patients with Acute Myocardial Infarction undergoing Percutaneous Coronary Intervention
Atrial Fibrillation (AF) is an established risk factor ischemic stroke (IS) and is commonly encountered in patient hospitalized with acute myocardial infarction (AMI). Uncommonly, IS can occur as a complication resulting from percutaneous coronary intervention (PCI). There is limited real world data regarding AF-associated in-hospital IS (IH-IS) in patients admitted with AMI undergoing PCI. We queried the National Inpatient Sample database from January 2010 to December 2014 to identify patients admitted with AMI who underwent PCI.
Source: The American Journal of Cardiology - December 29, 2020 Category: Cardiology Authors: Shivaraj Patil, Karthik Gonuguntla, Chaitanya Rojulpote, Manish Kumar, Srinivas Nadadur, Robert J. Nardino, Christopher Pickett Source Type: research

Risk of Stroke vs. Intracerebral Hemorrhage in Patients with Non-Valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Comparing Dual vs. Triple Antithrombotic Therapy
About 15% of patients with non-valvular atrial fibrillation might require percutaneous coronary interventions (PCIs) with stent placement to treat obstructive coronary artery disease. Dual antiplatelet therapy (DAPT) with acetylsalicylic acid (aspirin) and P2Y12 antagonist is recommended after PCI. Patients requiring DAPT also require treatment with oral anticoagulation for atrial fibrillation. We conducted a meta-analysis to identify the antithrombotic regimen associated with the lowest rate of bleeding and thromboembolic events in non-valvular atrial fibrillation after PCI.
Source: Journal of Stroke and Cerebrovascular Diseases - February 9, 2021 Category: Neurology Authors: Aaron Desai, Cesar Escamilla-Ocanas, Deepika Dilip, Hamidreza Saber, Rahul Damani Source Type: research

Stroke Risk Stratification With the CHADS2 Score in Patients Without Atrial Fibrillation Who Underwent Percutaneous Coronary Intervention
The clinical significance of the CHADS2 score remains unclear in patients with coronary artery disease (CAD) without atrial fibrillation (AF). Therefore, the purpose of this study was to evaluate the association between the CHADS2 score and the long-term risk of ischemic stroke and its severity in patients with CAD with and without AF. Using the CREDO (Coronary Revascularization Demonstrating Outcome study)-Kyoto Registry Cohort-3, the present study population consisted of 11,516 patients with CAD who underwent percutaneous coronary intervention without oral anticoagulants at discharge.
Source: The American Journal of Cardiology - August 13, 2022 Category: Cardiology Authors: Yuki Obayashi, Hiroki Shiomi, Takeshi Morimoto, Yodo Tamaki, Moriaki Inoko, Ryusuke Nishikawa, Kazuhisa Kaneda, Ko Yamamoto, Yasuaki Takeji, Akihiro Komasa, Kyohei Yamaji, Satoshi Shizuta, Tomohisa Tada, Kazuya Nagao, Satoru Suwa, Toshihiro Tamura, Hiroki Source Type: research